David Lebwohl Intellia Therapeutics, Inc. (NTLA) insider trading activity

David Lebwohl is EVP, Chief Medical Officer of Intellia Therapeutics, Inc.. Currently has a direct ownership of 87,666 shares of NTLA, which is worth approximately $894,193. The most recent transaction as insider was on Jan 03, 2025, when has been sold 9,557 shares (Common Stock) at a price of $12.18 per share, resulting in proceeds of $116,404. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 87.7K

5.81% 3M change

61.23% 12M change

Total Value Held $894,193

David Lebwohl Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 03 2025	SELL Open market or private sale	$116,404 $12.18 p/Share	9,557 Reduced 9.83%	87,666 Common Stock
Jan 01 2025	BUY Exercise of conversion of derivative security	-	3,189 Added 3.18%	97,223 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	38,701 Added 29.37%	93,073 Common Stock
Jan 03 2024	SELL Open market or private sale	$172,134 $29.46 p/Share	5,843 Reduced 9.7%	54,372 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	3,187 Added 5.03%	60,215 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	30,674 Added 35.24%	56,361 Common Stock
Jan 04 2023	SELL Open market or private sale	$95,778 $37.21 p/Share	2,574 Reduced 9.11%	25,687 Common Stock
Jan 01 2023	BUY Exercise of conversion of derivative security	-	3,187 Added 10.13%	28,261 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	13,816 Added 35.84%	24,738 Common Stock
Jan 01 2022	SELL Open market or private sale	$117,964 $112.24 p/Share	1,051 Reduced 8.78%	10,922 Common Stock
Jan 01 2022	BUY Exercise of conversion of derivative security	-	3,187 Added 21.02%	11,973 Common Stock
Nov 05 2021	SELL Open market or private sale	$320,256 $133.44 p/Share	2,400 Reduced 21.59%	8,714 Common Stock
Nov 05 2021	BUY Exercise of conversion of derivative security	$30,288 $12.62 p/Share	2,400 Added 17.76%	11,114 Common Stock
Oct 14 2021	SELL Open market or private sale	$309,144 $128.81 p/Share	2,400 Reduced 21.59%	8,714 Common Stock
Oct 14 2021	BUY Exercise of conversion of derivative security	$30,288 $12.62 p/Share	2,400 Added 17.76%	11,114 Common Stock
Sep 24 2021	BUY Exercise of conversion of derivative security	$99,988 $12.62 p/Share	7,923 Added 47.62%	8,714 Common Stock
Sep 21 2021	SELL Open market or private sale	$359,544 $149.81 p/Share	2,400 Reduced 75.21%	791 Common Stock
Sep 21 2021	BUY Exercise of conversion of derivative security	$30,288 $12.62 p/Share	2,400 Added 42.93%	3,191 Common Stock
Aug 30 2021	SELL Open market or private sale	$378,720 $157.8 p/Share	2,400 Reduced 75.21%	791 Common Stock
Aug 30 2021	BUY Exercise of conversion of derivative security	$30,288 $12.62 p/Share	2,400 Added 42.93%	3,191 Common Stock
Aug 09 2021	SELL Open market or private sale	$393,720 $164.05 p/Share	2,400 Reduced 75.21%	791 Common Stock
Aug 09 2021	BUY Exercise of conversion of derivative security	$30,288 $12.62 p/Share	2,400 Added 42.93%	3,191 Common Stock

David Lebwohl

EVP, Chief Medical Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Value

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA

Account